Bayer Invests in Startup Targeting Food-Related Allergies
Photographer: Krisztian Bocsi/Bloomberg
This article is for subscribers only.
Bayer AG’s impact investment arm is backing a company working to combat food-related allergies.
Leaps By Bayer led a $40 million funding round for Ukko Inc., a biotechnology startup founded in 2017, that is targeting proteins linked to gluten and peanuts that cause dietary restrictions and allergies in an effort to improve consumers’ health through the foods they eat.